VBI Vaccines (VBI Vaccines) Pre-Tax Income : $-92.84 Mil (TTM As of Dec. 2023)

View and export this data going back to . Start your Free Trial

What is VBI Vaccines Pre-Tax Income?

Pretax income is the income that a company earns before paying income taxes. VBI Vaccines's pretax income for the three months ended in Dec. 2023 was $-0.01 Mil. Its pretax income for the trailing twelve months (TTM) ended in Dec. 2023 was $-92.84 Mil. VBI Vaccines's pretax margin was -1.52%.

During the past 13 years, VBI Vaccines's highest Pretax Margin was -1069.29%. The lowest was -11054.36%. And the median was -4457.57%.

VBI Vaccines Pre-Tax Income Historical Data

The historical data trend for VBI Vaccines's Pre-Tax Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

VBI Vaccines Pre-Tax Income Chart

VBI Vaccines Annual Data

Trend

Mar14

Mar15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Pre-Tax Income

Get a 7-Day Free Trial

-54.81

-46.23

-69.75

-113.30

-92.84

VBI Vaccines Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Pre-Tax Income	Get a 7-Day Free Trial															-21.14	-27.75	-44.63	-20.44	-0.01

Competitive Comparison of VBI Vaccines's Pre-Tax Income

For the Biotechnology subindustry, VBI Vaccines's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

VBI Vaccines's Pre-Tax Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, VBI Vaccines's Pre-Tax Income distribution charts can be found below:

* The bar in red indicates where VBI Vaccines's Pre-Tax Income falls into.

VBI Vaccines Pre-Tax Income Calculation

This is the income that a company earns before paying income taxes.

VBI Vaccines's Pretax Income for the fiscal year that ended in Dec. 2023 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-55.311	+	-31.124	+	-8.064	+	1.663	+	0
	=	-92.84

VBI Vaccines's Pretax Income for the quarter that ended in Dec. 2023 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-12.364	+	14.072	+	-2.067	+	0.346	+	1.7884999037321E-15
	=	-0.01

Pre-Tax Income for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-92.84 Mil.

VBI Vaccines (OTCPK:SVACD) Pre-Tax Income Explanation

VBI Vaccines's Pretax Margin for the quarter that ended in Dec. 2023 is calculated as

Pretax Margin	=	Pretax Income	/	Revenue
	=	-0.013	/	0.853
	=	-1.52%

During the past 13 years, VBI Vaccines's highest Pretax Margin was -1069.29%. The lowest was -11054.36%. And the median was -4457.57%.

VBI Vaccines Pre-Tax Income Related Terms

Thank you for viewing the detailed overview of VBI Vaccines's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.

VBI Vaccines (VBI Vaccines) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » VBI Vaccines Inc (OTCPK:SVACD) » Definitions » Pre-Tax Income

Comparable Companies

Traded in Other Exchanges

VBIV:USA LO9A:Germany

Address

160 Second Street, Floor 3, Cambridge, MA, USA, 02142

Website

https://www.vbivaccines.com

VBI Vaccines Inc is a US-based commercial-stage, the biopharmaceutical company which is engaged in developing next-generation vaccines to address unmet needs in infectious disease and immuno-oncology. The company manufactures Sci-B-Vac product which is a hepatitis B (HBV) vaccine for adults, children, and newborns. Its products include Virus-Like Particle which is vaccine platform which allows for the design of enveloped virus-like particle vaccines that closely mimic the target viruses. The company operates through the single segment being Developing vaccines to address unmet needs in infectious disease and immuno-oncology.